Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Bookmark and Share
Published: 30 Sep 2019
Views: 349
Rating:
Save
Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA

Prof Ghassan Abou-Alfa presents data from the ClarIDHy trial during a press conference at the 2019 ESMO congress.

This was a phase III trial evaluating the use of the targeted therapy ivosidenib for advanced cholagiocarcinoma patients with the isocitrate dehydrogenase 1 (IDH1) mutation.

Watch Prof Abou-Alfa's interview with ecancer here.

Read more on the study here.